Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease

Angeliki Katsarou, Ioannis I Moustakas, Iryna Pyrina, Panagiotis Lembessis, Michael Koutsilieris, Antonios Chatzigeorgiou

Abstract

Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive storage of fatty acids in the form of triglycerides in hepatocytes. It is most prevalent in western countries and includes a wide range of clinical and histopathological findings, namely from simple steatosis to steatohepatitis and fibrosis, which may lead to cirrhosis and hepatocellular cancer. The key event for the transition from steatosis to fibrosis is the activation of quiescent hepatic stellate cells (qHSC) and their differentiation to myofibroblasts. Pattern recognition receptors (PRRs), expressed by a plethora of immune cells, serve as essential components of the innate immune system whose function is to stimulate phagocytosis and mediate inflammation upon binding to them of various molecules released from damaged, apoptotic and necrotic cells. The activation of PRRs on hepatocytes, Kupffer cells, the resident macrophages of the liver, and other immune cells results in the production of proinflammatory cytokines and chemokines, as well as profibrotic factors in the liver microenvironment leading to qHSC activation and subsequent fibrogenesis. Thus, elucidation of the inflammatory pathways associated with the pathogenesis and progression of NAFLD may lead to a better understanding of its pathophysiology and new therapeutic approaches.

Key words: Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Hepatic stellate cells; Inflammation; Liver fibrosis; Toll-like receptors; Nod-like receptors

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Non-alcoholic fatty liver disease (NAFLD) is defined as fatty acid accumulation in hepatocytes, called steatosis, in the absence of significant alcohol consumption or other known liver diseases. It is mostly attributed to conditions such as obesity, insulin resistance, microbiome disturbances and genetic predisposition[1-3]. NAFLD covers a spectrum of liver disorders, ranging from benign steatosis to steatohepatitis (NASH) or even cirrhosis and affects more than 40% of the population in western countries and approximately 25% of the world population[4]. The simple form of NAFLD is characterized by hepatic steatosis in at least 5% of hepatocytes without ballooning, while NASH is characterized by hepatic steatosis in at least 5% of hepatocytes with hepatocyte injury independent of fibrosis[5]. Thirty percent of patients with NAFLD will eventually develop NASH[4]. In these NAFLD patients, a gradual recruitment of cellular components of the immune system leads to inflammation as well as to tissue fibrosis[4], which are the two fundamental characteristics of NASH. Up until now it has been difficult to distinguish NAFLD from NASH in clinical practice and liver biopsy remains the gold standard method for the diagnosis of NAFLD and its progression to NASH[4,6]. The histological features of NASH are hepatic steatosis, hepatocellular ballooning and lobular inflammation which constitute the main components of the widely used NAFLD Activity Score (NAS)[5,7]. Importantly, hepatocyte ballooning is a feature denoting cellular injury characterized by enlarged swollen hepatocytes with or without Mallory-Denk bodies (MDB) in the cytoplasm[8]. Both ballooning of hepatocytes and MDB are the two hallmarks of ongoing inflammation; nevertheless the presence of MDB is supportive but not required for the diagnosis of steatohepatitis[7,9].

A key event in the progression of steatosis into NASH is the differentiation of hepatic stellate cells (HSCs) to myofibroblasts. Under normal conditions, quiescent HSCs are localized in Disse’s space in the liver where they store around 80% of the body’s vitamin A. In conditions of chronic stimulation, HSCs proliferate and produce extracellular matrix (ECM) proteins which contribute to the emergence and progression to hepatic fibrosis[10]. Although myofibroblasts can also be produced by portal fibroblasts and vascular smooth muscle cells, the main source of ECM during NASH development are activated HSCs[11-14]. Several mechanisms, including obesity-related low-grade inflammation and insulin resistance, as well as changes in the intestinal microbiome may trigger this process[15]. This review summarizes the current literature regarding the inflammatory mechanisms contributing to the progression of steatosis into liver fibrosis and NASH.
According to this hypothesis, NAFLD is induced by the simultaneous synergism of multiple factors such as insulin resistance, adipose tissue inflammation, oxidative damage as well as activation of Transforming growth factor-beta (TGF-β) in a pre-existing lipid-rich environment in the liver[19].

The initial event leading the transition of steatosis to NASH is the accumulation and storage of lipids as macrovesicular fat in the cytoplasm of the hepatocytes[10,19], which consists of fatty acids, ceramides, free-cholesterol, diacyl-glycerol and phospholipids[6]. This toxic lipid-induced hepatocyte injury, referred as lipotoxicity, leads to cellular stress, apoptosis and eventually cell death[20,21]. The apoptotic hepatocytes initiate an inflammatory process by secreting extracellular vesicles[21] which consist of exosomes, microvesicles or apoptotic bodies that contribute to intercellular communication in NASH pathogenesis[22,23]. More specifically, HSCs and Kupffer cells engulf the apoptotic bodies released from the hepatocytes, leading to the secretion of fibrogenic factors such as TGF-β, or inflammatory mediators such as Tumor necrosis factor-α (TNF-α)[24]. Additionally, cytokines and chemokines secreted by Kupffer cells promote the recruitment of other immune cells, further perpetuating the inflammatory process and HSC activation taking place under steatotic conditions in the liver[25]. Of note, obesity and metabolic dysregulation lead to alterations in the gut microbiome, thus provoking increased permeability of the small bowel and as a consequence further increasing fatty acid absorption as well as easier penetration by bacterial endotoxins[26]. These events may cause the gut microbiota to transverse the intestinal barrier and translocate to the liver thereby triggering the inflammatory response[27,28].

The “second hit” of the multiple hit hypothesis constitutes the continuous lipid buildup in hepatocytes during NAFLD thus inducing oxidative stress via mitochondrial overload leading to a “chronic-like” production of reactive oxygen species, cytokines and chemokines which are prerequisite mediators in NAFLD to NASH progression[29,30]. The increased oxidative stress, the cell death that ensues and the continuous unresolved inflammation perpetuate HSC activation that lead to fibrosis[31,32]. More precisely, in response to continuous exposure to cytokines and growth factors, qHSCs are getting activated and proliferate producing compounds of ECM[13], such as the collagen type I and type III, as well as Tissue inhibitor of metalloproteinases 1 (TIMP-1)[33], all contributing to fibrogenesis[32,33]. In addition, the engulfment of apoptotic bodies by HSCs confers on them a partial resistance to TNF and Fas ligand thereby gaining resistance against cell death[34]. Finally, the excessive production of ECM with a dominance of collagen leads to NAFLD-related liver fibrosis[31].

INGNATIVE IMMUNE PATHWAYS AND MEDIATORS LEADING TO METABOLISM-RELATED LIVER FIBROSIS

The role of inflammation is important in hepatic fibrogenesis during NAFLD[13]. Several immune cell populations of both the innate and adaptive immunity, already existing in the adult liver or recruited from the circulation during NAFLD, are implicated in this process[6,13]. Kupffer cells, recruited monocyte-derived macrophages, dendritic cells and neutrophils are major innate immune subpopulations involved in NAFLD to NASH transition, while T-cell subpopulations such as natural killer T (NKT) cells, T-helper 17 (Th17) cells and T-regulatory (Treg) cells are also of major importance[35,36]. Although the majority of the aforementioned cellular players are thought to provoke the emergence of hepatic fibrosis during NAFLD and metabolic dysregulation, a minority of them such as Treg, have a protective role, while evidence regarding others, such as dendritic cells remains controversial[6,35,36].

Pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain-like receptors (NOD-like receptors or NLRs) located predominantly on Kupffer but also on HSCs are essential for NAFLD-related fibrosis by recognizing Pathogen-associated molecular patterns (PAMPs) and Damage-associated molecular patterns (DAMPs)[35]. PAMPs are external danger signals principally expressed by microbes such as bacteria and parasites, but they can also be lipids, lipoproteins, proteins and nucleic acids[34]. DAMPs on the other hand constitute internal pathogenic agents such as HMGB1, S100 protein, heat shock proteins, hyaluronan and fibronectin[29] and in the case of NAFLD can be produced by damaged hepatocytes[36]. Activation of TLRs and NLRs by PAMPs and DAMPs in Kupffer cells as well as in HSCs during NAFLD leads to the secretion of cytokines such as TNF-α and interleukin-1β (IL-1β), thus provoking the progression to NASH. We herein describe the molecular inflammatory events taking place upon TLR and NLR activation in the steatotic liver, as well as the role of cardinal cytokines that lead
to the emergence and development of fibrosis during NAFLD.

TOLL-LIKE RECEPTORS

The TLR receptors comprise a group of 11 proteins in humans and 13 proteins in mice. In the liver, TLRs serve as PRRs on Kupffer cells and HSCs, but are also expressed by other cell types such as dendritic cells, endothelial cells, and hepatocytes[37]. TLRs are divided into two subpopulations according to their cellular localization. TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 are expressed exclusively on the cell surface and mainly recognize PAMPs, while TLR3, TLR7, TLR8 and TLR9 are localized in intracellular vesicles such as endosomes or lysosomes and the endoplasmic reticulum (ER) and predominantly recognize DAMPs[38,39]. Upon stimulation they activate two signaling pathways; the molecule adaptor protein myeloid differentiation factor 88 (MyD88)-dependent signaling pathway and/or the MyD88-independent pathway involving the TIR domain-containing adaptor (TRIF) resulting in the production of type I Interferons (IFNs). The former is common to all TLRs, except TLR3, and leads to the production of inflammatory cytokines while the latter is associated with the production of IFN-β and the maturation of dendritic cells and occurs via the Toll/IL-1R domain-containing adaptor-inducing IFN-β (TRIF)-dependent signaling regulatory factor 3 (IRF-3) responsible for type I IFN synthesis as well as inflammatory cytokines through associated NF-kB activation[40,41]. TLR2, TLR4 and TLR9 are expressed in both Kupffer cells and HSCs and their roles in the development of NASH is summarized below.

TLR2

Previous studies have shown a contributing role of TLR2 in the development of NASH. Miura et al[42] reported that TLR2 signaling in combination with palmitic acid increased the expression of proinflammatory cytokines including IL-1β, and an inflammasome component, Nod-like receptor protein 3 (NLRP3), in Kupffer cells but not in HSCs. TLR2−/− mice fed a choline-deficient, L-amino acid-defined (CDAA) diet, had reduced NAFLD activity score and diminished infiltration of inflammatory cells compared to wild-type mice. Concurrently, the expression of alpha-smooth muscle actin (α-SMA) was diminished, while the production of collagen α1 types I and IV mRNAs were reduced as was the expression of TGF-β1, TIMP-1 and Plasminogen Activator Inhibitor 1 (PAI-1) mRNA[43]. These data are in line with those of Ji et al[44] who showed that carbon tetrachloride (CCL4) administration in TLR2−/− mice resulted in diminished liver injury as indicated by reduced activation of HSCs, reduced deposition of collagen and reduced expression of several pro-fibrotic and pro-inflammatory genes including TNF-α, IL-6, Platelet-derived growth factor (PDGF), TGF-β and TIMP-1. Furthermore Ji et al[44] showed that the CCI4-induced phosphorylation of ERK1/2, p38 and JNK signaling pathways as well as impaired NF-kB activation were significantly diminished in TLR2−/− mice compared with WT mice, strongly suggesting that TLR2 may promote the fibrogenesis via activating MAPK and NF-kB signaling pathways[45]. Another study by Szabo et al[46] 2005 investigated the roles of TLR2 and TLR4 in liver damage and on cytokine induction in a methionine-choline deficient (MCD) diet-induced model of NASH. They reported that MCD diet-induced steatohepatitis in mice results in the sensitization of TLR4 but not to TLR2-induced liver injury. In contrast to the aforementioned studies they showed that steatohepatitis in TLR2−/- mice results in increased liver injury as evidenced by elevated ALT and TNF-α levels suggesting a potential protective role for TLR2 in fatty liver.

TLR4

The contribution of TLR4 in NASH pathogenesis has been widely studied. The TLR4 receptor is primarily activated by lipopolysaccharide (LPS) of Gram negative bacteria, as well as by HMGB1, hyaluronan, saturated fatty acids, fibronectin, heat shock proteins 60 and 70, degraded matrix and DAMPs secreted by damaged cells[46,47]. However, bacterial products such as bacterial flagellin, bacterial toxins, and LPS or DNA from the gut remain the main promoters of TLR4 activation[48]. TLR4 is expressed by Kupffer cells and HSCs. The TLR4 dimer associates with the adaptor protein myeloid differentiation protein 2 (MD-2) on Kupffer cells and HSCs which in turn bind indirectly to the bacterial endotoxin lipid A. Lipid A is the lipophilic domain of circulating LPS and forms the main cell wall component of Gram negative bacteria. The resulting active TLR4/MD-2/LPS complex binds extracellularly and initiates a signaling cascade that leads to the activation of NF-kB and the production of pro-inflammatory cytokines leading to inflammatory and immune responses[49]. In this manner, Kupffer cells participate in pro-inflammatory
and pro-fibrogenic cytokine production, while activated HSCs secrete ECM[49], as well as chemokines, promoting further chemotaxis of immune cells in the liver[50].

Liu et al[49] employing a NAFLD animal model provided convincing evidence of the involvement of TLR4 in NASH development. They investigated TLR4 signaling at different stages of NAFLD induced by a high-fat, high fructose (HFHFr) diet in TLR4-mutant and in control wild-type mice and assessed the pathological characteristics of the liver. After 8 weeks and 16 weeks of HFHFr feeding, the WT mice showed increased AST and ALT levels compared to TLR4-mutant mice. Furthermore, as early as week 4, histopathological evaluation showed that the HFHFr-fed wild type mice exhibited micro and macrovesicular steatosis; by week 8 they demonstrated hepatocellular ballooning and lobular inflammation and by week 16 they showed notable fibrosis while TLR4 mutant mice fed the same diet for the same length of time showed significantly reduced fibrosis. Their data suggest that TLR4 signaling is a major link between inflammation and fibrosis in NAFLD. Of note, the TLR4 receptor downregulates TGF-β pseudoreceptor Bambi via MyD88-NF-kB pathway suggesting that HSCs respond to TGF-β induced signals[51]. In addition, liver biopsies obtained from obese women undergoing RYGB (Roux-en-Y Gastric Bypass) operation showed increased TLR4 and IRF3 expression in subjects with NAFLD compared with those with NAFLD[52]. Interestingly, a study investigating the status of bacterial translocation in cirrhotic liver found that in NASH liver tissue, even if bacterial colonization was decreased, TLR4 mRNA and its protein product were increased compared to the control group[53].

**TLR9**

TLR9 is located in the endoplasmic reticulum of dendritic cells, macrophages, endothelial cells and hepatocytes and principally recognizes non-methylated CpG sequences in DNA of bacteria[54,55]. LPS upregulates the expression of TLR9 in murine macrophages in a NF-kB- and MAPK-dependent manner[55]. Evidence obtained from the human hepatic stellate cell line LX-2 cells as well as from primary mouse HSCs, indicate that TLR9 also participates in HSC differentiation. DNA along with CpG fragments released by apoptotic hepatocytes led to an increase of TGF-β1 and collagen I mRNA in HSCs, implying activation of the latter via TLR9 stimulation[55]. In a murine experimental model of NASH induced by CDA diet, the Kupffer cells of TLR9+/− mice showed reduced expression of IL-1β, while the mice showed less steatohepatitis and fibrosis in comparison to wild-type control mice[56]. Indeed, translocated bacterial DNA seems to bind to TLR9 of Kupffer cells promoting the secretion of IL-1β which in turn promotes hepatocyte damage and death via lipid accumulation, while inducing HSC activation, thus leading to steatohepatitis and fibrosis[55]. In another study by Gäbele et al[57], activation of HSCs derived from TLR9+/− mice by CpGs of bacterial DNA led to increased monocyte chemoattractant protein-1 (MCP-1) mRNA compared to those from TLR9−/− mice, indicating that MCP-1 secretion from HSCs strongly depends on the activation of TLR9.

**NOD-LIKE RECEPTORS STRUCTURE AND FUNCTION**

Nucleotide binding oligomerization domain-like receptors (NLRs) comprise a family of conserved, cytosolic innate immune PRRs essential in detection of PAMPs and DAMPs, including cytosolic microbial and danger components, as well as molecules emanating from damaged or disrupted cells[58]. All members of the NLR family are defined by a central NACHT or NOD domain responsible for oligomerization and nucleotide-binding which mediates the activation of the transduction complex. The majority of NLRs also have a C-terminal domain which is rich in leucine repeats (LRRs), acting as a sensor of ligands, whereas a caspase recruitment or pyrin or a baculovirus inhibitor repeats domain (CARD, PYD and BIR respectively) is situated in the N-terminal region of NLRs. Homotypic interactions resulting to downstream signaling are implemented by this N-terminal domain[59]. Importantly, depending on the type of the N-terminal domain, the NLR family is divided into 4 main subfamilies, namely NLR-A, NLR-B, NLR-C, and NLR-P (A for acidic transactivating domain, B for BIRs, C for CARD and P for PYD)[60], while NLR-X is an additional subfamily namely NLR-A, NLR-B, NLR-C, and NLR-P (A for acidic transactivating domain, B for BIRs, C for CARD and P for PYD)[60], while NLR-X is an additional subfamily

NLRs include positive regulators of inflammation, such as the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3), and anti-inflammatory ones such as NLRX1 and NLRP12[60,61]. Upon activation, the majority of NLRs oligomerize to form multiprotein inflammasome complexes which are high-molecular-weight cytosolic multiprotein complexes in the cytosol of host cells that regulate pathogen recognition,
host defense, and inflammatory processes. The activation of inflammasome occurs as a consequence of infection or other form of cellular stress and damage, such as fragments of double stranded DNA, amyloid β, hyaluronic acid and monosodium urate\cite{66-68}. The NLRP3 is the most studied inflammasome to date. This cytosolic structure of proteins is formed in a two-step process including priming, as a result of overexpression by TLR signaling, and triggering, which is orchestrated by K⁺ efflux as a result of increased production of reactive oxygen species, originating from damaged mitochondria and lysosome destabilization both leading to inflammation. Assembly of the NLRP3 inflammasome interacts with caspase-1 leading to its activation and upon activation, caspase-1 promotes the maturation of the proinflammatory cytokines IL-1β and IL-18 following cleavage of their precursors Pro-IL-1β and Pro-IL-18\cite{69}. In addition, caspase-1 activates gasdermin D which is responsible for pore formation leading to a form of cell death called pyroptosis. This proinflammatory type of cell death is a consequence of activation of inflammasome leading to the release of cytoplasmic components including the inflammatory cytokines\cite{70-72}.

**NLR in NASH**

Growing evidence indicates the association of the innate immune system in sensing cellular stress originating from deregulated metabolic conditions. In the case of NAFLD, upregulation and overactivity of cellular and molecular components of the immune system, like the NLR inflammasomes, is believed to be the “effector links” for the progression of steatosis into NASH.

NLR signaling and activation of inflammasomes is believed to take place not only in innate immune cells like macrophages and neutrophils but also in non-immune cells in the liver, such as hepatocytes, endothelial cells and HSCs\cite{73}. An upregulation in the expression of NLRP3 inflammasome components has been observed in livers of mice fed a MCD diet, suggesting the participation of several hepatic cellular players, apart from immune cells, in the initiation of inflammation and progression to NASH\cite{74}. Indeed, murine hepatocytes have demonstrated activation of the NLRP3 inflammasome and subsequent caspase-1-dependent secretion of IL-1β after treatment with palmitic acid and LPS, while danger signals that are released from hepatocytes under the same conditions are able to activate liver mononuclear cells in a paracrine-dependent manner\cite{75}. Similarly, cultured HSCs deriving from rats show significant increase in expression of several NLR family members, including NLRP1, NLRP3 and NLRC4 after treatment with LPS, while hepatocytes were predominantly characterized by strong NLRP3 activation\cite{76}. Furthermore, in palmitate-treated Kupffer cells, the release of IL-1β and IL-18 was shown to be dependent on NLRP3 inflammasome activation\cite{77}.

Genetic or pharmacological manipulations of NLR inflammasomes in mice have provided important information in scrutinizing their role in the progression of NAFLD. The contribution of inflammasome in metabolic dysfunction and NAFLD has been observed in knockout mice for NLRP3, which were fed a HFD, and displayed improved insulin resistance, accompanied by attenuated fat deposition in the liver and reduced adipocyte size in the adipose tissue\cite{78}. Oppositely, continuous NLRP3 activation led to NASH development characterized by deteriorated inflammation and fibrosis in murine models of diet-induced NAFLD\cite{79}. Along this line, a recent study in mice revealed that liver fibrosis and inflammation in a setting of experimental NASH were attenuated after administration of a molecular NLRP3 inhibitor\cite{80}. Importantly, pyroptosis that is induced in hepatocytes upon NLRP3 activation and results in the release of inflammatory mediators outside of the pyroptotic cell, is thought to be a major mechanism of propagating inflammation and further perpetuating NLR signaling to adjacent cells in the liver, such as HSCs\cite{81-83}.

Apart from experimental animal studies, clinical studies in individuals with metabolic syndrome have indicated the causal link between IL-1β and IL-18, as products of inflammasome activation, to the development of metabolic dysregulation\cite{71}. For instance, the grade of NLRP3 expression in adipose tissue of obese individuals correlates to the severity of type 2 diabetes mellitus in a direct fashion\cite{72}. Accordingly, NLRP3 and caspase-1 expression levels are elevated in the liver of individuals with NASH\cite{73}. In human HSC cultures, inflammasome components have been identified as essential for inflammatory and fibrotic rearrangements following application of monosodium urate crystals\cite{80}.

**CYTOKINES**

Several cytokines, such as IL-1, IL-6, PDGF and TGF-β, secreted both by immune cells as well as by parenchymal cells of the liver during NAFLD contribute to the
progression of the disease into NASH by promoting hepatic fibrosis via the activation of HSCs. Apart from the cytokines produced and secreted within the liver microenvironment, cytokines derived from adipose tissue are also important instigators of the aforementioned process. Especially under obese conditions, the adipose tissue is characterized by the production of TNF-α and IL-6 by adipocytes and macrophages which in turn target the liver inducing hepatic insulin resistance as well as fat deposition and fibrosis.

TNF-α and PDGF are involved in the earlier phases of NAFLD-related liver inflammation when the main changes are matrix degradation, migration and cell proliferation. On the other hand, TGF-β is critical in later stages of inflammation, when matrix accumulation outweighs degradation. It should be emphasized that resident and recruited macrophages produce PDGF, TGF-α, TNF-α and insulin-like growth factor-1 (IGF-1) which function as mitogenic agents for HSCs. Interestingly, the HSCs themselves produce TGF-α and TGF-β after their activation. The latter acquires an autocrine action inducing HSCs proliferation. Herein, we describe the implication of cardinal cytokines involved in HSC activation and their differentiation to myofibroblasts.

**TNF-α**

The importance of TNF-α in NASH and hepatic fibrosis is supported by many studies. A study including obese patients, demonstrated a significant increase of TNF-α mRNA expression in livers derived from individuals with significant hepatic fibrosis in comparison to those who were not characterized by liver fibrosis. Similarly, in a cross-sectional study with patients with NASH, a correlation between TNF-α along with collagen type IV and the stage of fibrosis was found. In wild type mice fed with CDAA, an increased activity of TNF-α converting enzyme, which cleaves pro-TNF-α into the active form of TNF-α, as well as increased production of TNF-α, collagen α1, and TGF-β have been reported.

In principle, TNF-α is mainly produced by macrophages as a response to different bacterial products such as LPS and exerts its action via the binding to TNF receptors (TNFR) 1 and 2. In the case of hepatic injury, such as during NAFLD-induced hepatocyte damage, the released PAMPs and DAMPs induce the activation of innate immune cells that secrete cytokines such as TNF-α, IL-6 and IL-1α. The main source of hepatic TNF-α are hepatocytes and Kupffer cells, while abdominal fat also participates.

TNF-α has been found to suppress the apoptosis of primary cultured HSCs through the increase of TIMP-1 mRNA expression, while simultaneously contributes to their survival and proliferation. In models of hepatic cirrhosis, a continuous activation of HSCs was observed (as defined by α-SMA staining), as a result of persistent TIMP-1 mRNA expression. Along this line, TNFRI seems to be involved in HSC activation. HSCs derived from TNFR1- or TNFR1/TNFR2 double-knockout mice, but not from TNFR2 knockout mice, showed reduced mRNA expression of procollagen-α1 as compared to those derived from wild type mice. Consistently, TNFR1/TNFR2 double-knockout mice are characterized by improved steatosis and fibrosis when exposed to a MCD diet, as compared to wild-type control mice.

**IL-1α / IL-1β**

Among the members of the IL-1 family, IL-1α and IL-1β are the most broadly studied in NAFLD. They are predominantly secreted by hepatic macrophages and play a major role in all stages of the disease including deterioration of insulin signaling, hepatic lipid accumulation and induction of fibrosis.

Kamari et al. investigated the role of the proinflammatory cytokines IL-1α and IL-1β in steatohepatitis. They reported that atherogenic diet-induced steatohepatitis in wild-type mice was associated with significant increases in the mRNA levels of hepatic IL-1α and IL-1β; while, oppositely, mice deficient in either IL-1α or IL-1β showed reduced transformation of steatosis to steatohepatitis and liver fibrosis in spite of increased cholesterol levels. Indeed, IL-1β is thought to induce lipid accumulation in hepatocytes via IL-1 receptor (IL-1R). More precisely, under NAFLD conditions, Kupffer cells highly secrete IL-1β which in turn mediates the development of liver steatosis via NF-κB stimulation in hepatocytes that leads to suppression of peroxisome proliferator-activated receptor alpha activity. In addition, IL-1β seems to contribute directly to the development of fibrosis. In rat HSCs, IL-1b was shown to induce MMP-13 gene expression, by acting via the JNK and p38 MAPK pathways, thus influencing the remodeling of ECM and promoting fibrosis. Similarly, reduced liver steatosis and fibrosis was observed in IL-1R-deficient mice when diet-induced
models of NASH were used\cite{96,97}.

On the contrary, the IL-1R antagonist (IL-1Ra) is thought to have an anti-inflammatory role in liver diseases\cite{98} and mice deficient for IL-1Ra fed an atherogenic diet showed severe steatosis and fibrosis in the liver compared to wild type mice fed the same diet\cite{99}. Nevertheless, in a study including 6447 men, the serum levels of IL-1Ra correlated with NASH and serum ALT independently of obesity, consumption of alcohol or insulin resistance\cite{100}.

**IL-6**

IL-6 is a pro-inflammatory cytokine with an obscure role in NASH. During obesity, the protein levels of IL-6 in the adipose tissue correlate with the degree of insulin resistance\cite{101}, while its mRNA levels correlate with those of CRP\cite{102}. A study using liver biopsies from patients with NAFLD showed elevated hepatic IL-6 levels in patients with NASH compared to those with only steatosis or normal liver biopsy, which also correlated with the circulating levels of IL-6\cite{103}. Similarly, in obese patients, the blood levels of IL-6 seem to be higher in those with severe steatosis in comparison with those with mild steatosis\cite{104}. Of note, adipose tissue IL-6 expression correlates to the degree of NAFLD progression among obese individuals\cite{105}. Another study investigating the influence of diet and aerobic exercise with or without the administration of vitamin E on cytokines showed increased TNF-α, IL-8 and IL-6 levels, both in plasma and in peripheral blood monocytes, in patients with NASH compared to controls. However, after the intervention, only IL-6 in plasma was reduced\cite{106}.

Despite the clinical observations, mechanistic studies using animal models provide controversial evidence. Already in 2002, Wallenius et al\cite{107} showed that genetic ablation of IL-6 in mice is associated with the development of mature onset obesity and insulin resistance. In mice fed a MCD diet, intraperitoneal administration of the IL-6 receptor antibody MR16-1 was shown to block the IL-6/gp130 pathway resulting in reduced hepatic injury, but at the same time increased lipid accumulation and hepatic steatosis\cite{108}. Oppositely, when IL-6 was administered into HFD-fed mice led to upregulation of lipogenesis-related genes and deterioration of hepatic steatosis\cite{109}. Interestingly, IL-6, in a Stat-3 dependent way, induces the expression of Indy, which is a citrate transporter receptor that favors hepatic lipogenesis\cite{110}.

**TGF-β**

TGF-β is major mediator of HSC activation and hepatic fibrosis in chronic liver diseases; nevertheless, it is involved in several cellular processes such as cell survival, proliferation and angiogenesis\cite{111}. TGF-β signaling is taking place in a SMAD- and non-SMAD dependent way. The former is thought to be the “canonical”- TGF-β signaling pathway mediated by phosphorylation of the SMAD proteins, while the latter is mediated by activation of other pathways such as the MAPK or the PI3K/AKT pathways\cite{112}. TGF-β exists in three isoforms, namely TGF-β1, 2, and 3 which share some common but not equal functions, with TGF-β1 being the most extensively studied in the field of hepatic fibrosis\cite{112,113}. In the liver, Kupffer cells constitute the main source of TGF-β, while during fibrosis it can also be produced by stellate and endothelial cells\cite{114}. In particular, during obesity and NAFLD, leptin deriving from the obese adipose tissue stimulates the production of TGF-β1 from Kupffer cells\cite{115}.

The involvement of TGF-β1 in hepatic fibrosis has been under intense investigation for more than two decades. Indeed, in 1992, Annoni et al\cite{116} showed that liver biopsies from patients with active liver disease and fibrosis displayed increased hepatic expression of TGF-β1, which positively correlated to the mRNA levels of procollagen α1. Similarly, multiple studies have demonstrated that the hepatic mRNA levels of TGF-β are increased in patients with NASH and fibrosis\cite{117,118}. Nevertheless, existing data regarding the diagnostic value of circulating TGF-β1 levels in reflecting the presence of fibrosis and the progression of steatosis into NASH are contradictory\cite{119,120}. In line with the evidence obtained from human studies, CCl4-induced hepatic fibrosis in mice is associated with increased expression of TGF-β1 in the livers of these mice\cite{121,122}. Along this line, TGF-β1 deficiency in mice leads to reduced hepatic expression of collagen α1 and α-SMA upon CCl4 administration, consistent with reduced fibrosis, while adenovirus-mediated TGF-β1-overexpression induced their expression\cite{123}. During obesity and metabolic dysregulation, TGF-β exerts its action via the TGF-β-SMAD pathway and genetic deletion of SMAD3 in mice is associated with protection from insulin resistance and liver steatosis in HFD-induced obesity\cite{124}. Noteworthy, wild-type mice fed a CDA diet showed increased activation of SMAD2/3, deteriorated liver steatosis, inflammation as well as hepatocyte death and fibrosis compared to hepatocyte-specific TGF-β receptor type II-deficient mice\cite{125,126}. Overall, TGF-β participates both in lipid accumulation as well as to NASH...
progression during NAFLD.

**PDGF**

Platelet-derived growth factor (PDGF) is produced by hepatic macrophages, activated HSCs as well as by platelets. It boosts HSC migration and proliferation and a loss of vitamin A which is normally stored into quiescent HSCs. PDGF is a dimeric polypeptide that can consist of the same or different subunits. Four different types of PDGF subunits have been identified namely PDGF-A, -B, -C and D, which can be combined into five different PDGF polymers, namely PDGF-AA, -BB, -AB, -CC, and -DD. PDGF binds to PDGF receptors-a and -b, which are present on endothelial cells, macrophages and fibroblasts including the HSCs, and affects cell proliferation, cell migration, angiogenesis while it promotes alterations in membrane structure. In HSCs, it also participates in the synthesis of ECM by inducing secretion of collagen and other ECM components. PDGF binding to its receptors activates predominantly the Ras-MAPK pathway leading to the aforementioned cellular reactions and molecular changes.

Several studies have highlighted the role of the PDGF family of ligands in liver fibrosis, including their action during metabolic dysregulation and NAFLD. Of note, PDGF-B and PDGF-D are major stimuli of HSCs’ proliferation and activation in contrast to PDGF-A and PDGF-C that do not equally provoke a fibrogenic response by the HSCs in vitro. Nevertheless, hepatic overexpression not only of PDGF-B, but also of PDGF-A or PDGF-C in mice was able to induce fibrosis in the liver. Consistently, antiviruses-mediated suppression of PDGF-B production attenuated liver fibrosis in a short-term BDL model in rats. Similarly, fibrosis was improved after vaccination with PDGF-B kinoid immunogens in mice that were subjected to CCl4-induced fibrosis. In the context of NASH, increased expression of PDGF-AA in the liver is associated with elevated risk for the development of insulin resistance and steatohepatitis in humans, while PDGF-C seems to be an instigator of steatosis into NASH progression both in humans and rodents.

**GUT MICROBIOME AND NAFLD**

The gut flora is one of the main regulating factors for the development of NAFLD. Under normal conditions, the gut microbiota has beneficial effects to host health such as contribution to digestion as well as to immune defense by maintaining the integrity of gastrointestinal barrier and by participating in immunomodulation. Although to a limited extent, bacterial products present in the gastrointestinal system are able to reach the liver via the portal vein. When the intestinal barrier, that normally plays a protective role against a plethora of pathogens, is disrupted and gut permeability is increased, bacterial translocation is possible. Indeed, a meta-analysis based on human studies showed that patients with NAFLD and NASH had increased intestinal permeability compared to control subjects, while other studies have reported correlations between microbiota composition and NAFLD development. For instance, in a study by Le Roy et al., C57BL/6J wild-type mice were fed a high-fat diet for 16 weeks and then divided into two groups according to the development of metabolic dysregulation and systemic inflammation. The first group that displayed hyperglycemia and inflammation was defined as “responder” and the second one displaying normal blood glucose as “non-responder”. When gut microbiota from these two groups were transferred to germ-free mice, the “responder-receiver” group displayed high blood glucose and insulin, along with liver steatosis, suggesting that the composition of the microbiome may influence glucose homeostasis and the development of hepatic steatosis. Another study by Boursier et al. reported a correlation between gut dysbiosis and the severity of NAFLD in humans. Briefly, in stool samples derived from NAFLD patients, the presence of *Bacteroides* was associated to that of NASH, while *Ruminococcus* abundance was correlated with important fibrosis.

Among the microbial components participating in NAFLD pathogenesis are LPS, peptidoglycan (PGN), flagellin, lipoteichoic acid, unmethylated CpG motifs, short-chain fatty acids (SCFAs), and bacterial DNA, having either detrimental or beneficial effect on liver steatosis. LPS is a component of the outer membrane of Gram-negative bacteria and its circulating levels have been reported to be increased during NAFLD in animal as well as in human studies. Indeed, as mentioned above, LPS may promote the development of NAFLD via binding to TLR4 expressed in immune as well as parenchymal cells of the liver. Interestingly, a 4-week high fat diet in mice provokes elevation of plasma LPS and a shift to a more LPS-containing microbiome in the gut. Of note, the same study showed that the...
A plethora of molecules and signaling pathways are involved in the inflammatory process that accompanies the development of liver fibrosis during NAFLD (Figure 1 and Table 1). Signal transduction pathways downstream of TLRs and NLRs are of considerable interest for the activation and perpetuation of the innate immune response implicated in the development of liver fibrosis during metabolic dysregulation and liver steatosis and understanding of the mechanisms and molecules involved therein may lead to novel approaches against the progression of steatosis into NASH or cirrhosis.

The current strategy for the treatment of fibrosis is based on the modification of lifestyle factors, such as reduction of body weight in combination with exercise and healthy nutrition, as well as pharmaceutical improvement of insulin resistance. Specifically, a 3%-5% reduction of body weight alleviates steatosis; a greater reduction improves histopathological findings of NASH and fibrosis. Metformin is not officially prescribed for NASH; pioglitazone induces histological changes in patients with or without diabetes mellitus, while there is no sufficient evidence for the use of GLP-1 agonists. Several preclinical studies, predominantly in mouse models of fibrosis and NASH, provide innovative approaches for the management of inflammatory process during NAFLD-related fibrosis. For instance, the suppression of NLRP3 inflammasome by the pharmacological agent sulforaphane improved aspects of inflammatory process during NAFLD-related fibrosis. Thus, intestinal microbiota-derived PGN is able to promote hepatic lipogenesis and fibrosis via an NOD2-NFκB-PPARγ pathway-related mechanism.

SCFAs, including propionate, butyrate and acetate, are predominantly produced by anaerobic microbiota of the colon upon fragmentation of dietary fiber. In contrast to LPS and PGN, the role of SCFAs in the development of NAFLD steatosis seems to be rather protective and anti-inflammatory. Indeed, in the epithelium of the gastrointestinal tract, SCFAs bind to the “metabolite-sensing” receptors GPR43 and GPR109A, inducing the expression of IL-18, thus protecting gut barrier integrity. Besides, butyrate was found to induce colonic Treg cell differentiation, thereby contributing to intestinal immune homeostasis. In addition, SCFAs trigger the secretion of Glucagon-Like Peptide-1 (GLP-1) by the intestinal enteroendocrine L-cells, which in turn ameliorates NAFLD development and progression by provoking fatty acid oxidation in the liver. Interestingly, this phenomenon may function in a positive feedback mode since sodium butyrate was found to induce the hepatic expression of GLP-1 receptor and attenuate NAFLD in mice subjected to a high fat diet. Similarly, in humans, propionate administration for 24 weeks triggered GLP-1 and peptide YY secretion, leading to attenuated hepatic lipid accumulation and improved insulin resistance.

CONCLUSION

Apart from the necessity for identifying novel therapies against NASH, there is a need for the development of new, reliable, safe and less invasive diagnostic methods sensitive enough to detect NAFLD even at its initial stage, where it is thought to be reversible and benign. Currently, a liver biopsy is considered the gold standard for the diagnostic confirmation and estimation of disease severity, as well as for the discrimination between NAFLD and NASH. Less invasive methods include blood tests of liver function, ultrasound, and proton magnetic resonance spectroscopy (H-MRS). Only cytokeratin-18 released during cell apoptosis and cell death can be used as a measure for histological changes, but it lacks specificity and sensitivity.
Table 1  Pathways and mediators of liver fibrosis during non-alcoholic fatty liver disease

| Mediator | Expression in the liver | Function during NAFLD |
|----------|-------------------------|------------------------|
| TLR2     | Kupffer cells, HSCs     | Promotion of fibrogenesis via activation of MAPK and NF-κB signaling pathways |
| TLR4     | Kupffer cells, HSCs     | Induction of inflammation and fibrosis in a NF-κB-dependent way |
| TLR9     | Kupffer cells, HSCs     | HSC differentiation, secretion of IL-1β from Kupffer cells and MCP-1 from HSCs |
| TLR9     | Innate immune cells, hepatocytes, endothelial cells and HSCs | NAFLD and NASH development via inflammasome activation and release of IL-1β and IL-18 |
| TNF-α    | Kupffer cells, hepatocytes | Promotion of liver fibrosis by inducing the survival and proliferation of HSCs |
| IL-1α/IL-1β | Kupffer cells | Stimulation of hepatocyte lipid accumulation and induction of fibrosis via MMP production and suppression of PPARα in HSCs |
| IL-6     | Immune cells, Kupffer cells | Induction of hepatic lipogenesis in a Stat-3 dependent way |
| TGF-β    | Kupffer cells, endothelial cells, HSCs | Induction of HSC activation and proliferation mainly via TGF-β-SMAD pathway |
| PDGF     | Kupffer cells, activated HSCs, platelets | Induction of HSC migration, activation and proliferation via Ras-MAPK pathway |

PPARα: Proliferator-activated receptor alpha activity; PDGF: Platelet-derived growth factor; NAFLD: Non-alcoholic fatty liver disease; HSCs: Hepatic stellate cells; NASH: Non-alcoholic steatohepatitis.

Other serum biomarkers under investigation include TGF-β and the associated markers R58 and L59/LAP-DPs; these are produced by the cleavage of Latency-associated protein (LAP) which is the pro-peptide of TGF-β162-163.

Overall, metabolic inflammation is thought to be the causal mechanistic link for the progression of steatosis into NASH and scrutinization of the implicating factors may pave the way for the development of new diagnostic tools and therapeutic strategies for the prevention or treatment of the disease.
Figure 1  Innate immune pathways and mediators involved in the development of liver fibrosis during non-alcoholic fatty liver disease. Activation of the HSCs is the major event during the development of liver fibrosis. Various mediators released from parenchymal as well as non-parenchymal cells of the liver, as well as from metabolic organs (adipose tissue, gut) can promote HSCs activation. TGF-β and PDGF, mainly produced by liver macrophages, have a central role in hepatic fibrogenesis. HSCs start to produce TGF-β, PDGF and MCP-1 after their activation. Autocrine production of TGF-β and PDGF by activated HSCs induces their further proliferation. Hepatic macrophages, lymphocytes and endothelial cells secrete IL-1α and IL-1β. These molecules participate in the initial extracellular matrix degradation by induction of MMP2, MMP3 and MMP13 expression by HSCs, while are also implicated in HSC survival and proliferation. IL-1β, in particular, induces the expression of TIMP-1, PAI-1 and collagen. In addition, pro-inflammatory cytokines such as IL-1β, IL-6 and TNF-α can induce lipid accumulation in hepatocytes and in turn cause hepatocyte injury and inflammation. Apoptotic hepatocytes secrete reactive oxygen species, vascular endothelial growth factor and IGF1, which can activate hepatic macrophages. Pyroptosis can also contribute to the development of fibrosis via activation of NLRs in HSCs. Of note, TLR2, TLR4 and TLR9, expressed by liver macrophages and HSCs are the key Toll-like receptors in the pathophysiology of NASH and metabolism-related liver fibrosis by provoking the expression of pro-inflammatory and pro-fibrotic cytokines by these cells.

REFERENCES

1 Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002; 17 Suppl: S186-S190 [PMID: 12000605 DOI: 10.1046/j.1440-1746.17.s1.10.x]
2 Ray K. NAFLD-the next global epidemic. Nat Rev Gastroenterol Hepatol 2013; 10: 621 [PMID: 24185985 DOI: 10.1038/norgastro.2013.197]
3 Papatheodoridi AM, Chrysavgis L, Koutsilieris M, Chatzigeorgiou A. The Role of Senescence in the Development of Nonalcoholic Fatty Liver Disease and Progression to Nonalcoholic Steatohepatitis. Hepatology 2020; 71: 363-374 [PMID: 31230380 DOI: 10.1002/hep.30834]
4 Ibrahim SH, Hirsova P, Gores GJ. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut 2018; 67: 963-972 [PMID: 29367207 DOI: 10.1136/gutjnl-2017-315691]
5 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012; 107: 811-826 [PMID: 22641309 DOI: 10.1038/ajg.2012.128]
a mitochondrial NOD-like receptor that amplifies NF-kappaB and JNK pathways by inducing reactive oxygen species production.

Tattoli I, Carneiro LA, Jéhanno M, Magalhaes JG, Shu Y, Philpott DJ, Arnoult D, Girardin SE. NLRX1 is a mitochondrial NOD-like receptor that amplifies NF-kappaB and JNK pathways by inducing reactive oxygen species production. *Cell* 2010; 145: 135-145 [PMID: 21258359 DOI: 10.1038/cmi.2010.81]

Conforti-Andreoni C, Ricciardi-Castagnoli P, Mortellaro A. The inflammasomes in health and disease: a comprehensive update. *Cell Mol Immunol* 2011; 8: 285-287 [PMID: 20940109 DOI: 10.1038/cmi.2010.99]

Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espeskog T, Golenbock DT. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. *Nat Immunol* 2004; 5: 190-198 [PMID: 14716310 DOI: 10.1038/nm1082]

An H, Xu H, Yu Y, Zhang M, Qi R, Yan X, Liu S, Wang W, Gao Z, Qin Z, Cao X. Up-regulation of TLR9 gene expression by LPS in mouse macrophages via activation of NF-kappaB, ERK and p38 MAPK signal pathways. *Immunol Lett* 2002; 81: 165-169 [PMID: 11947920 DOI: 10.1016/S0165-2478(02)00010-X]

Watanabe A, Hashmi A, Gomes DA, Town T, Badou A, Flavell RA, Mehal WZ. Apoptotic hepatocyte death signals and liver regeneration. *Immunol Lett* 2004; 95: 135-140 [PMID: 15378847 DOI: 10.1016/j.imml.2003.11.031]

J Reconstr Microsurg 2008; 24: 251-256 [PMID: 18401983 DOI: 10.1053/j.mrm.2007.12.005]

Maioli A, Kanegami TD. Inflammasome activation and assembly at a glance. *J Cell Sci* 2017; 130: 3955-3963 [PMID: 29196474 DOI: 10.1242/jcs.207365]

Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation. *Nat Rev Immunol* 2019; 19: 477-489 [PMID: 31036962 DOI: 10.1038/s41577-019-0165-0]

Cookson BT, Brennan MA. Pro-inflammatory programmed cell death. *Trends Microbiol* 2001; 9: 113-114 [PMID: 11303500 DOI: 10.1016/S0966-842X(00)01936-3]
Trends Mol Med 2018; Mirea AM, Tack CJ, Chavakis T, Joosten LAB, Toonen EJM. IL-1 Family Cytokine Pathways and liver fibrogenesis. Hepatology 2012; 54: 133-144 [PMID: 21488666 DOI: 10.1002/hep.24341]

Boarù SG, Borkham-Kamporst E, Thiaù L, Haas U, Weiskirchen R. Expression analysis of inflammatory cytokines in inflammatory and fibrotic liver disease. J Innamm (Lond) 2012; 9: 49 [PMID: 23192004 DOI: 10.1186/1476-9255-9-49]

Cai C, Zhu X, Li P, Li J, Gong J, Shen W, He K. NLRP3 Deletion Inhibits the Non-alcoholic Steatohepatitis Development and Inflammation in Kupffer Cells Induced by Palmitic Acid. Inflammation 2018; 41: 1857-1883 [PMID: 28705152 DOI: 10.1007/s10753-017-0628-z]

Stenstrøm R, van Diepen JA, Tack CJ, Zaki MH, van de Venrooen FL, Perera D, Neale GA, Hooiveld GJ, Hjimans A, Vroegrijk J, van den Berg S, Romijn J, Rensen PC, Joosten LA, Neetä MG, Kanmeganti TD. Inflammation is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci USA 2011; 108: 15324-15329 [PMID: 21871267 DOI: 10.1073/pnas.1100255108]

Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, Hoffman HM, Feldstein AE. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 2014; 59: 826-910 [PMID: 23813942 DOI: 10.1002/hep.26592]

Mridha AR, Wree A, Robertson AAB, Yeh MM, Johnson CD, Van Rooyen DM, Hazceyni F, Teoh NC, Savard C, Ioanou GN, Masters SL, Schroder K, Cooper MA, Feldstein AE, Farrell GC. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol 2017; 66: 1037-1046 [PMID: 28167322 DOI: 10.1016/j.jhep.2017.01.022]

Baraja-Mazo A, Martín-Sánchez F, Gomez Al, Martínez CM, Amores-Iniesta J, Compan V, Barberá-Cremades M, Yagüe J, Ruiz-Oritz É, Antón B, Antón B, Cuillín I, Brough D, Arostegui J, Pelegrín P. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol 2014; 15: 738-746 [PMID: 24952508 DOI: 10.1038/ni.2919]

Franklin BS, Bossaller L, De Nardo D, Ratter JM, Statz A, Engels G, Brockerhoff C, Nordhoff M, Mirandola SR, Al-Anoudi A, Mangan MS, Zimmer S, Monks BG, Fricke M, Schulte RE, Espevii T, Jones B, Jarnicki AE, Hansbro PM, Busto P, Marshak-Rothstein A, Horsemann S, Aguzzii A, Kastenmüller W, Latz E. The adaptor ASC has extracellular and prionoid activities that propagate inflammation. Nat Immunol 2014; 15: 727-737 [PMID: 24952509 DOI: 10.1038/ni.2915]

Fève B, Bastard JP. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5: 305-311 [PMID: 19399017 DOI: 10.1038/nrendo.2009.62]

Vandannamgbar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179-188 [PMID: 21217695 DOI: 10.1038/nm.2279]

Watazabe A, Sohail MA, Gomes DA, Hashmi A, Nagata J, Sturnow FA, Mahmoud S, Bandier MN, Shi Y, Flavell RA, Mehal WZ. Inflammasome-mediated regulation of hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1248-G1257 [PMID: 19359429 DOI: 10.1152/ajpgi.90223.2008]

Chung KJ, Nati M, Chavakis T, Chatzigeorgiou A. Innate immune cells in the adipose tissue. World J Gastroenterol 2009; 15: G583-G589 [PMID: 19773234 DOI: 10.3748/wjg.v15.i8.727]

NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 2014; 59: 826-910 [PMID: 23813942 DOI: 10.1002/hep.26592]

Franklin BS, Bossaller L, De Nardo D, Ratter JM, Statz A, Engels G, Brockerhoff C, Nordhoff M, Mirandola SR, Al-Anoudi A, Mangan MS, Zimmer S, Monks BG, Fricke M, Schulte RE, Espevii T, Jones B, Jarnicki AE, Hansbro PM, Busto P, Marshak-Rothstein A, Horsemann S, Aguzzii A, Kastenmüller W, Latz E. The adaptor ASC has extracellular and prionoid activities that propagate inflammation. Nat Immunol 2014; 15: 727-737 [PMID: 24952509 DOI: 10.1038/ni.2915]

Fève B, Bastard JP. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5: 305-311 [PMID: 19399017 DOI: 10.1038/nrendo.2009.62]

Vandannamgbar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179-188 [PMID: 21217695 DOI: 10.1038/nm.2279]

Watazabe A, Sohail MA, Gomes DA, Hashmi A, Nagata J, Sturnow FA, Mahmoud S, Bandier MN, Shi Y, Flavell RA, Mehal WZ. Inflammasome-mediated regulation of hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1248-G1257 [PMID: 19359429 DOI: 10.1152/ajpgi.90223.2008]

Chung KJ, Nati M, Chavakis T, Chatzigeorgiou A. Innate immune cells in the adipose tissue. World J Gastroenterol 2009; 15: G583-G589 [PMID: 19773234 DOI: 10.3748/wjg.v15.i8.727]
Katsarou A et al. Inflammation and liver fibrosis

29665983 DOI: 10.1016/j.molmed.2018.03.005

93 Kamari Y, Shaish A, Vax E, Shemesh S, Kandel-Kfir M, Arbel Y, Oleante S, Barshack I, Dotan S, Voronov E, Dinarello CA, Apte RN, Harats D. Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol 2011; 55: 1086-1094 [PMID: 2134522 DOI: 10.1016/j.jhep.2011.01.048]

94 Stienstra R, Saudafe F, Duval C, Keshkat S, Groener JE, van Rooijen N, Staels B, Kersten S, Müller M. Kupffer cells promote hepatic steatosis via interleukin-1β-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 2010; 51: 511-522 [PMID: 20545688 DOI: 10.1002/hep.23337]

95 Tang N, Zhang YP, Ying W, Yao XQ. Interleukin-1β upregulates matrix metalloproteinase-13 gene expression via e-Jun N-terminal kinase and p38 MAPK pathways in rat hepatocellular stellate cells. Mol Med Rep 2013; 8: 1861-1865 [PMID: 24126863 DOI: 10.3892/mmr.2013.1719]

96 de Rosa B, Rungapanichay S, Ross K, Lacklidge G, Reid M, Duncanson B, Horgan G, Toomey S, Browne J, Loscher CW, Mills KH, Roche HM. Attenuation of inflammation and cellular stress-related pathways maintains insulin sensitivity in obese type 1 interleukin-1 receptor knockout mice on a high-fat diet. Proteomics 2009; 9: 3244-3256 [PMID: 19562798 DOI: 10.1002/pmic.200800761]

97 Gielen RG, Wallace K, Han YP. Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1324-G1331 [PMID: 19342509 DOI: 10.1152/ajpgi.90564.2008]

98 Niederreiter L, Tilg H. Cytokines and fatty liver diseases. Liver Research 2018; 2: 14-20 [DOI: 10.1016/j.livres.2018.03.003]

99 Isoda K, Sawada S, Ayaori M, Matsuki T, Horai R, Kagaya Y, Miyazaki K, Kusuhara M, Okazaki M, Matsubara O, Iwakura Y, Ohsumi Y. Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice. J Biol Chem 2005; 280: 7002-7009 [PMID: 15574426 DOI: 10.1074/jbc.M412220200]

100 Pihlajamäki K, Kualasamtaa T, Kaminiska D, Simonen M, Kärjä V, Grönlund S, Kälkel P, Pääkkönen M, Kainulainen N, Pumonen K, Kuusisto J, Gylling H, Laakso M. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J Hepatol 2012; 56: 663-670 [PMID: 22027586 DOI: 10.1016/j.jhep.2011.10.005]

101 Bastard JP, Maechi M, Van Shiu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 2002; 87: 2088-2089 [PMID: 11994345 DOI: 10.1210/jevim.87.5.9459]

102 Anty R, Bekri S, Luciani N, Saint-Paul MC, Dahman M, Iannelli A, Amor IB, Staccini-Myx A, Huet PM, Gugenheim J, Sadoul JL, Le Marchand-Brustel Y, Tran A, Guelf P. The inflammatory C-reactive protein is increased in both adipose tissue and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH. Am J Gastroenterol 2006; 101: 1824-1833 [PMID: 16790033 DOI: 10.1111/j.1572-0241.2006.00749.x]

103 Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human non-alcoholic steatohepatitis. Am J Gastroenterol 2008; 103: 1372-1379 [PMID: 18516018 DOI: 10.1111/j.1572-0241.2007.01774.x]

104 García-Galiano D, Sánchez-Garritano MA, Espejo I, Montes JL, Costán G, Marchal T, Membrives A, Gallardo-Valverde JM, Muñoz-Castañeda JR, Arévalo E, De la Mata M, Muntané J. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg 2007; 17: 493-503 [PMID: 17608262 DOI: 10.1007/s11695-007-9087-1]

105 Jorge ASB, Andrade JMO, Paraiso AF, Jorge GCB, Silveira CM, de Souza LR, Santos EP, Guimarães ALS, Santos SHS, De-Paula AMB. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity. Obes Rev Clin Pract 2018; 12: 1-8 [PMID: 27083404 DOI: 10.1016/j.orecp.2016.03.009]

106 Kuglmas M, Hill DB, Viviam B, Marsano L, McClain CJ. Cytokines and NASI: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 413-419 [PMID: 12983485 DOI: 10.1053/jhep.2003.50316]

107 Wallenius V, Wallenius K, Ahrein B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002; 8: 75-79 [PMID: 11786910 DOI: 10.1038/nm1002-753]

108 Yamaguchi K, Itoh Y, Yokomizo C, Nishimura T, Niimi T, Fujii H, Okanoue T, Chiyokawa M, Tsuchihashi T. Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. J Biol Chem 2010; 285: 1169-1178 [PMID: 20368703 DOI: 10.1038/labinvest.2010.75]

109 Vida M, Gavito AL, Pavon FJ, Bautista S, Serrano A, Suarez J, Arrabal S, Decara J, Romero-Cuevas M, Rodriguez de Fonseca F, Baixeras E. Chronic administration of recombinant IL-6 upregulates lipoprotein enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice. Dis Model Mech 2015; 8: 721-731 [PMID: 26035366 DOI: 10.1242/dmm.019166]

110 von Loefelholz C, Lieske S, Neuschäfer-Rube F, Niederreiter L, Tilg H, Demirbas Z, Kral T, Ozturk C, Zeiher AM, Schömig A, Ziemer KD. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 2002; 87: 2088-2089 [PMID: 11994345 DOI: 10.1210/jevim.87.5.9459]

111 Dewidar B, Meyer C, Dooley S, Meindl-Beinaker AN. TGF-β1 in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019. Cells 2019; 8 [PMID: 31710844 DOI: 10.3390/cells8111419]

112 De Blaser PJ, Niki T, Rogiers V, Geerts A. Transforming growth factor-beta gene expression in normal and fibrotic rat liver. J Hepatol 1997; 26: 866-893 [PMID: 9126804 DOI: 10.1016/S0168-8278(97)80257-7]

113 Wang J, Leclercq I, Brymora JM, Xu N, Ramezani-Moghadam M, London RM, Brigstock D, George J. Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology 2009; 137: 713-723 [PMID: 19375424 DOI: 10.1053/j.gastro.2009.04.011]

114 Annoni P, Doelz FR, Zern MA. Increased transforming growth factor-beta 1 gene expression in human
liver disease. *J Hepatol* 1992; 14: 259-264 [PMID: 1380023 DOI: 10.1016/0168-8278(92)00186-O]

116 Klein S, Mittenöther B, Eagon JC, Patterson B, Grant L, Fein N, Seki E, Brenner D, Korenblat K, McCrea J. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. *Gastroenterology* 2006; 130: 1564-1572 [PMID: 16997719 DOI: 10.1053/j.gastro.2006.01.042]

117 Cayón A, Crespo J, Mayorga M, Guerra A, Pons-Romerò F. Increased expression of Ob-Rb and its relationship with the overexpression of TGF-β1 and the stage of fibrosis in patients with nonalcoholic steatohepatitis. *Liver Int* 2006; 26: 1065-1071 [PMID: 17032406 DOI: 10.1111/j.1478-3231.2006.01337.x]

118 Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. *Aliment Pharmacol Ther* 2001; 15: 1667-1672 [PMID: 11564008 DOI: 10.1046/j.1365-2036.2001.01183.x]

119 Tarantini G, Conca P, Riccio A, Tarantini M, Di Mimo MN, Chiavese D, Pasanisi F, Contaldo F, Seopacassa F, Capone D. Elovathwash factor-beta1 in simple fatty liver: is it really benign? *J Transl Med* 2008; 6: 72 [PMID: 19038040 DOI: 10.1186/1477-5876-6-72]

120 Sepúlveda-Flores RN, Vera-Cabrera L, Flores-Gutiérrez JP, Maldonado-Garza H, Salinas-Garza R, Zorrilla-Blanco P, Bosques-Padilla FJ. Obesity-related non-alcoholic steatohepatitis and TGF-β1 serum levels in relation to morbid obesity. *Ann Hepatol* 2002; 1: 36-39 [PMID: 15141294 DOI: 10.1016/S1665-2681(19)31980-8]

121 Ajmera V, Perito ER, Baa S, Mollart NA, Yates KP, Gill R, Loomba R, Diel MH, Aouizerat BE; NASH Clinical Research Network. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. *Hepatology* 2017; 65: 65-77 [PMID: 27532276 DOI: 10.1002/hep.28776]

122 Czaja MJ, Flanders KC, Biempiica L, Klein C, Zern MA, Weiner FR. Expression of tumor necrosis factor-alpha and transforming growth factor-beta1 in acute liver injury. *Growth Factors* 1989; 1: 221-226 [PMID: 2698219 DOI: 10.1089/089719898699998]

123 Niu L, Cui X, Q. Y, Xie D, Wu Q, Chen X, Ge J, Liu Z. Involvement of TGF-β1/Smad3 Signaling in Carbon Tetrachloride-Induced Acute Liver Injury in Mice. *PloS One* 2016; 11: e0156990 [PMID: 27224266 DOI: 10.1371/journal.pone.0156900]

124 Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA. The role of TGFβ1 in initiating hepatic stellate cell activation in vivo. *J Hepatol* 1999; 30: 77-87 [PMID: 9927153 DOI: 10.1016/s0168-8278(99)00101-5]

125 Tan CK, Leuenberger N, Tan MJ, Yan YW, Chen Y, Kambadur R, Wahi W, Tan NS. Smad3 deficiency in mice protects against insulin resistance and obesity induced by a high-fat diet. *Diabetes* 2011; 60: 464-476 [PMID: 21270569 DOI: 10.23736/S0012-7240.10.11986-0]

126 Yang L, Roh YS, Song J, Zhang B, Liu C, Loomba R, Seki E. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell cycle and lipid metabolism in mice. *Hepatology* 2014; 59: 483-495 [PMID: 23996730 DOI: 10.1002/hep.26698]

127 Yadav H, Quijano C, Kamaraju AK, Gavirolava O, Malek R, Chen W, Zerlas P, Zhigang D, Wright EC, Stuelten C, Sun P, Lonning S, Skarulis M, Sumner AE, Finkel T, Rane SG. Protection from obesity and diabetes by blockade of TGF-β1/Smad3 signaling. *Cell Metab* 2011; 14: 67-79 [PMID: 21723505 DOI: 10.1016/j.cmet.2011.04.013]

128 Ying HZ, Chen Q, Zhang WY, Zhang HH, Ma Y, Zhang SZ, Fang J, Yu CH. PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review). *Mol Med Rep* 2017; 16: 7879-7889 [PMID: 28983598 DOI: 10.3892/mmr.2017.7641]

129 Failli P, Ruocco C, De Franco R, Caligiuri A, Gentilini A, Giotti A, Gentilini P, Pinzani M. The mitogenic effect of platelet-derived growth factor in human hepatic stellate cells requires calcium influx. *Am J Physiol* 1995; 269: C1133-C1139 [PMID: 7491901 DOI: 10.1152/ajpcell.1995.269.3.C1133]

130 Borkham-Kamporst H, Meerur SK, Van de Leur E, Haas U, Tihai L, Weiskirchen R. PDGF-D signaling in portal myofibroblasts and hepatic stellate cells proves identical to PDGF-B via both PDGF receptor type α and β. *Cell Signal* 2015; 27: 1305-1314 [PMID: 25819339 DOI: 10.1016/j.cellsig.2015.03.012]

131 Thieringer F, Maas T, Czochra P, Klopich B, Conrad I, Friebe D, Schirmacher P, Lohse AW, Blessing M, Galle PR, Teufel A, Kanzler S. Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-B. *Gastroenterology* 2016; 150: 130-1312 [PMID: 25568192 DOI: 10.1053/j.gastro.2016.01.042]

132 Camoll J, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, Odell MM, Galle PR, Teufel A, Kanzler S. Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-B. *Gastroenterology* 2005; 129: 3389-3394 [PMID: 15728360 DOI: 10.1016/j.gastro.2004.06.153]

133 Abderrahmani A, Yengo L, Caiazzo R, Canoill M, Cauchi S, Raverey V, Plaisance V, Pawlowsk V, Lobbens S, Matile J, Rolland J, Bouthy R, Queniat G, Wampliner M, Tenenbaum B, Bricambert J, Saussenhouser S, Anthony E, Jha P, Deroig J, Sand O, Bazarchoolv L, Dore M, Pagiray S, Duarte P, Medicri M, Duaht-Chavanin M, Gerbal-Chaloin S, Dayeh T, Lassailly G, Mathurin P, Stefanis A, Auverux J, Schirman M, Pastic S, Schaffmayer C, Hamps J, Bonnefond A, Pattou F, Frugol P. Increased Hepatic PDGF-AA Signaling Mediates Liver Insulin Resistance in Obesity-Associated Type 2 Diabetes. *Diabetes* 2018; 67: 1301-1321 [PMID: 29722033 DOI: 10.2337/db17-1539]

134 Wright JH, Johnson MM, Shimizu-Alberginger M, Baer RL, Hayes BJ, Surapitatchit J, Hukdins KI, Riehle KJ, Johnson SC, Yeh MM, Bammler TK, Beyer RP, Gilbertson DG, Alpers CE, Fausto N, Campbell JS. Paracrine activation of hepatic stellate cells in platelet-derived growth factor C transgenic mice: evidence for stromal induction of hepatocellular carcinoma. *Int J Cancer* 2014; 134: 778-788 [PMID: 23929039 DOI: 10.1002/ijc.28421]

135 Zhu L, Baker RD, Baker SS. Gut microbiome and nonalcoholic fatty liver diseases. *Pediatr Res* 2015; 77:
Deng W, Meng Z, Sun A, Yang Z. Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study. Cancer Biomark 2017; 20: 411-415 [PMID: 28946547 DOI: 10.3233/CBM-170157]

European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402 [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.001]
Yokoyama H, Masaki T, Inoue I, Nakamura M, Mezaki Y, Saeki C, Oikawa T, Saruta M, Takahashi H, Ikegami M, Hano H, Ikejima K, Kojima S, Matsuura T. Histological and biochemical evaluation of transforming growth factor-β activation and its clinical significance in patients with chronic liver disease. *Heliyon* 2019; 5: e01231 [PMID: 30815603 DOI: 10.1016/j.heliyon.2019.e01231]

Hara M, Inoue I, Yamazaki Y, Kirita A, Matsuura T, Friedman SL, Rifkin DB, Kojima S. LAP degradation products serve as a promising blood biomarker for liver fibrogenesis in mice. *Fibrogenesis Tissue Repair* 2015; 8: 17 [PMID: 26379781 DOI: 10.1186/s13069-015-0034-9]
